Form 4: Immunovant COO Melanie Gloria Receives Stock Options and Restricted Stock Units

Immunovant's Chief Operating Officer, Melanie Gloria, was granted stock options and restricted stock units as part of her compensation.

Summary

• Melanie Gloria, the Chief Operating Officer of Immunovant, Inc., received 109,956 restricted stock units (RSUs) and stock options for 137,446 shares on November 18, 2024.
• The RSUs and stock options were granted under the company's 2019 Equity Incentive Plan.
• The RSUs will vest 25% on November 18, 2025, and the remaining 75% will vest in 12 equal quarterly installments over the following three years.
• The stock options also vest 25% on November 18, 2025, with the remaining 75% vesting in 12 equal quarterly installments over the following three years.
• Both the RSUs and stock options are subject to Ms. Gloria's continued employment with Immunovant.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating a positive but not extraordinary event. The vesting schedule suggests a long-term commitment from the executive.

Positives

• The grant of RSUs and stock options aligns the COO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the COO.

Risks

• The value of the RSUs and stock options is dependent on the future performance of Immunovant's stock price.
• If Ms. Gloria leaves the company before the vesting dates, she may forfeit unvested RSUs and stock options.

Future Outlook

The vesting of the RSUs and stock options is contingent on Ms. Gloria's continued service to the company.

Industry Context

The granting of stock options and restricted stock units is a common practice in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the biotech industry.
• Vesting schedules of 25% after one year and the remainder over three years are typical for these types of grants.
• Companies like Regeneron, Amgen, and Biogen also use similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders may view this as a positive sign of aligning management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, equity compensation, insider trading, Immunovant, IMVT, Melanie Gloria, COO